75302-98-6Relevant academic research and scientific papers
Preparation method of acemetacin
-
Paragraph 0010, (2020/12/05)
The invention discloses a preparation method of acemetacin. The preparation method comprises the following steps: (1) introducing hydrogen chloride into glacial acetic acid to prepare an acetic acid solution of hydrogen chloride; (2) adding acetic anhydride into the acetic acid solution of hydrogen chloride prepared in the step (1); (3) adding acemetacin tert-butyl ester into the hydrogen chloride-acetic acid-acetic anhydride mixed acidolysis solution obtained in the step (2), and stirring at a constant temperature; (4) after the reaction is finished, cooling, carrying out standing crystallization, filtering, and carrying out top-washing to obtain a crude product acemetacin; and (5) refining the crude product acemetacin to obtain the finished product acemetacin. The invention provides a preparation method of acemetacin, wherein the influence of moisture in raw materials on an acidolysis reaction of acemetacin tert-butyl ester is eliminated on the premise of adopting the existing equipment, so that the product yield is increased, the production cost is lowered, and the economic benefit is improved.
Nitrosated nonsteroidal antiinflammatory compounds, compositions and methods of use related applications
-
Page/Page column 52, (2010/11/30)
The invention describes novel nitrosated nonsteroidal antiinflammatory drugs (NSAIDs) and pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated NSAID, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or at least one therapeutic agent. The invention also provides novel compositions comprising at least one nitrosated NSAID, and at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one therapeutic agent. The invention also provides novel kits comprising at least one nitrosated NSAID, and, optionally, at least one nitric oxide donor and/or at least one therapeutic agent. The invention also provides methods for treating inflammation, pain and fever; for treating gastrointestinal disorders; for facilitating wound healing; for treating and/or preventing gastrointestinal, renal and/or respiratory toxicities resulting from the use of nonsteroidal antiinflammatory compounds; for treating inflammatory disease states and/or disorders; and for treating and/or preventing ophthalmic diseases and/or disorders.
